Based in Boston, Alexion Pharmaceuticals is a globalbiopharmaceutical company focused on serving patients and familiesaffected by rare diseases through the innovation, development, andcommercialization of life-changing therapies. The company does asignificant amount of business in 15 different currencies, soforeign exchange (FX) risk is top-of-mind for the treasury team.Nevertheless, when Alexion's revenue quadrupled over just fouryears, the sophistication of its FX processes needed to increasecommensurately.

“A few years ago, we had two people in Switzerland placinghedges at a transactional level,” explains Jeff Hynes, assistanttreasurer. “They used spreadsheets to track the company's balancesheet and cash flow risks. They would look at each invoice orpayable coming in and decide whether to hedge it on a one-offbasis. It worked, but only because of the brute force they wereapplying in terms of manpower.”

Complete your profile to continue reading and get FREE access to Treasury & Risk, part of your ALM digital membership.

  • Critical Treasury & Risk information including in-depth analysis of treasury and finance best practices, case studies with corporate innovators, informative newsletters, educational webcasts and videos, and resources from industry leaders.
  • Exclusive discounts on ALM and Treasury & Risk events.
  • Access to other award-winning ALM websites including PropertyCasualty360.com and Law.com.
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Meg Waters

Meg Waters is the editor in chief of Treasury & Risk. She is the former editor in chief of BPM Magazine and the former managing editor of Business Finance.